2016 Q4 Form 10-Q Financial Statement
#000119312516764344 Filed on November 09, 2016
Income Statement
Concept | 2016 Q4 | 2016 Q3 | 2015 Q4 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $1.490M | $1.420M | $2.360M |
YoY Change | -36.86% | -27.92% | 47.5% |
% of Gross Profit | |||
Research & Development | $2.820M | $2.494M | $3.830M |
YoY Change | -26.37% | -18.03% | 60.92% |
% of Gross Profit | |||
Depreciation & Amortization | $10.00K | $9.482K | $0.00 |
YoY Change | -15.78% | -100.0% | |
% of Gross Profit | |||
Operating Expenses | $4.310M | $3.914M | $6.190M |
YoY Change | -30.37% | -21.99% | 55.53% |
Operating Profit | -$4.314M | -$3.914M | -$6.192M |
YoY Change | -30.32% | -21.99% | 55.42% |
Interest Expense | $110.0K | -$110.0K | $390.0K |
YoY Change | -71.79% | -121.15% | -17.02% |
% of Operating Profit | |||
Other Income/Expense, Net | $40.00K | $66.98K | -$10.00K |
YoY Change | -500.0% | 43.55% | -150.0% |
Pretax Income | -$4.160M | -$3.954M | -$5.820M |
YoY Change | -28.52% | -11.13% | 66.76% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$4.163M | -$3.954M | -$5.815M |
YoY Change | -28.41% | -11.13% | 66.62% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$50.18K | -$47.67K | -$70.27K |
COMMON SHARES | |||
Basic Shares Outstanding | 82.87M shares | 82.87M shares | 82.82M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2016 Q4 | 2016 Q3 | 2015 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $40.40M | $44.70M | $58.40M |
YoY Change | -30.82% | -29.05% | 48.6% |
Cash & Equivalents | $13.89M | $17.64M | $28.24M |
Short-Term Investments | $26.50M | $27.10M | $30.20M |
Other Short-Term Assets | $1.000M | $300.0K | $1.500M |
YoY Change | -33.33% | -78.57% | -67.39% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $41.45M | $45.06M | $59.90M |
YoY Change | -30.8% | -29.99% | 36.67% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $244.2K | $249.0K | $191.5K |
YoY Change | 27.49% | 26.01% | 168.36% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Total Long-Term Assets | $253.1K | $257.9K | $200.4K |
YoY Change | 26.27% | 24.89% | 149.72% |
TOTAL ASSETS | |||
Total Short-Term Assets | $41.45M | $45.06M | $59.90M |
Total Long-Term Assets | $253.1K | $257.9K | $200.4K |
Total Assets | $41.71M | $45.31M | $60.10M |
YoY Change | -30.61% | -29.82% | 36.88% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $933.2K | $1.055M | $1.794M |
YoY Change | -47.99% | 29.17% | -1.11% |
Accrued Expenses | $1.161M | $940.3K | $1.646M |
YoY Change | -29.46% | -41.23% | -59.25% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $2.095M | $1.996M | $3.441M |
YoY Change | -39.12% | -16.37% | -41.24% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $300.0K | $400.0K | $1.200M |
YoY Change | -75.0% | -73.33% | -57.14% |
Total Long-Term Liabilities | $300.0K | $400.0K | $1.200M |
YoY Change | -75.0% | -73.33% | -57.14% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.095M | $1.996M | $3.441M |
Total Long-Term Liabilities | $300.0K | $400.0K | $1.200M |
Total Liabilities | $2.398M | $2.410M | $4.625M |
YoY Change | -48.16% | -38.41% | -46.63% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$108.1M | -$104.0M | -$90.08M |
YoY Change | 20.06% | 23.41% | 28.97% |
Common Stock | $82.97K | $82.87K | $82.85K |
YoY Change | 0.15% | 0.21% | 19.87% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $39.31M | $42.90M | $55.48M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $41.71M | $45.31M | $60.10M |
YoY Change | -30.61% | -29.82% | 36.88% |
Cashflow Statement
Concept | 2016 Q4 | 2016 Q3 | 2015 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$4.163M | -$3.954M | -$5.815M |
YoY Change | -28.41% | -11.13% | 66.62% |
Depreciation, Depletion And Amortization | $10.00K | $9.482K | $0.00 |
YoY Change | -15.78% | -100.0% | |
Cash From Operating Activities | -$4.410M | -$3.280M | -$4.640M |
YoY Change | -4.96% | -38.58% | 16.58% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$10.00K | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $590.0K | $2.200M | $50.00K |
YoY Change | 1080.0% | -7433.33% | 400.0% |
Cash From Investing Activities | $580.0K | $2.200M | $50.00K |
YoY Change | 1060.0% | -4500.0% | -600.0% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 80.00K | 0.000 | 70.00K |
YoY Change | 14.29% | -100.0% | -96.15% |
NET CHANGE | |||
Cash From Operating Activities | -4.410M | -3.280M | -4.640M |
Cash From Investing Activities | 580.0K | 2.200M | 50.00K |
Cash From Financing Activities | 80.00K | 0.000 | 70.00K |
Net Change In Cash | -3.750M | -1.080M | -4.520M |
YoY Change | -17.04% | -75.89% | 108.29% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$4.410M | -$3.280M | -$4.640M |
Capital Expenditures | -$10.00K | $0.00 | $0.00 |
Free Cash Flow | -$4.400M | -$3.280M | -$4.640M |
YoY Change | -5.17% | -38.46% | 17.17% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2016Q3 | us-gaap |
Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
|
568031 | |
CY2016Q3 | us-gaap |
Assets Current
AssetsCurrent
|
45055290 | |
CY2014Q1 | cprx |
Maximum Amount Of Common Stock That Can Be Issued Under Shelf Registration Statement
MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement
|
100000000 | |
CY2016Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
82870649 | shares |
CY2015Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
2979038 | |
CY2016Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
122224 | |
CY2015Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32750459 | |
CY2015Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
1397959 | |
CY2016Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
445325 | |
CY2016Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
940271 | |
CY2016Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2016Q3 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8888 | |
CY2016Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
|
1125366 | |
CY2016Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
101516 | |
CY2016Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2016Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
82870649 | shares |
CY2016Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
82870649 | shares |
CY2016Q3 | us-gaap |
Assets
Assets
|
45313216 | |
CY2016Q3 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
18093 | |
CY2016Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
CY2016Q3 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
185095 | |
CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
17638100 | |
CY2016Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
82871 | |
CY2016Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1055324 | |
CY2016Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
37853 | |
CY2016Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
146805233 | |
CY2016Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
940271 | |
CY2016Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
229172 | |
CY2016Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2016Q3 | us-gaap |
Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
|
185095 | |
CY2016Q3 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
36153 | |
CY2016Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2016Q3 | us-gaap |
Prepaid Rent
PrepaidRent
|
19660 | |
CY2016Q3 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
78323 | |
CY2016Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2016Q3 | us-gaap |
Liabilities
Liabilities
|
2409862 | |
CY2016Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
45313216 | |
CY2016Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1995595 | |
CY2016Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
24957 | |
CY2016Q3 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
26538304 | |
CY2016Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2016Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
249038 | |
CY2016Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
350554 | |
CY2016Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26538304 | |
CY2016Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42903354 | |
CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2451662 | shares |
CY2016Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-103984750 | |
CY2016Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
310855 | |
CY2016Q3 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
229172 | |
CY2016Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5150000 | shares |
CY2016Q3 | cprx |
Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
|
287793 | |
CY2016Q3 | cprx |
Prepaid Research Fee
PrepaidResearchFee
|
112971 | |
CY2016Q3 | cprx |
Prepaid Subscription Fees
PrepaidSubscriptionFees
|
36893 | |
CY2016Q3 | cprx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
126250 | |
CY2016Q3 | cprx |
Certificates Of Deposit Fair Value Disclosure
CertificatesOfDepositFairValueDisclosure
|
568031 | |
CY2016Q3 | cprx |
Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
|
26855 | |
CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9096778 | |
CY2014Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
2794891 | |
CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
894846 | |
CY2015Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1646476 | |
CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8888 | |
CY2015Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
|
1822769 | |
CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
70074 | |
CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
82850619 | shares |
CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
82850619 | shares |
CY2015Q4 | us-gaap |
Assets
Assets
|
60101570 | |
CY2015Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
18093 | |
CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
59901133 | |
CY2015Q4 | us-gaap |
Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
|
3717229 | |
CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
CY2015Q4 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
176293 | |
CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28235016 | |
CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
82851 | |
CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1794127 | |
CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
330490 | |
CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
145469078 | |
CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1646476 | |
CY2015Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
1008363 | |
CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
|
176293 | |
CY2015Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
34716 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2015Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
1252 | |
CY2015Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
436726 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
4625259 | |
CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
60101570 | |
CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3440603 | |
CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
17642 | |
CY2015Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
26444150 | |
CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
191549 | |
CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
261623 | |
CY2015Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26444150 | |
CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
55476311 | |
CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-90075618 | |
CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1504738 | |
CY2015Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1008363 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2015Q4 | cprx |
Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
|
332905 | |
CY2015Q4 | cprx |
Prepaid Research Fee
PrepaidResearchFee
|
915194 | |
CY2015Q4 | cprx |
Prepaid Subscription Fees
PrepaidSubscriptionFees
|
26602 | |
CY2015Q4 | cprx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
52500 | |
CY2015Q4 | cprx |
Certificates Of Deposit Fair Value Disclosure
CertificatesOfDepositFairValueDisclosure
|
3717229 | |
CY2015Q4 | cprx |
Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
|
90248 | |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
1721523 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5727663 | shares | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
23653681 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.18 | ||
us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
1721523 | ||
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6236942 | ||
us-gaap |
Depreciation
Depreciation
|
28382 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
324591 | ||
us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
34873869 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
113464 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1010221 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
14206673 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-14417800 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-14417800 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-56976 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-997189 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
341220 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14206673 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
37094556 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
32071 | ||
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1895738 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-13383899 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
23465 | ||
us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | ||
us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
4.64 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7969731 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
324949 | ||
us-gaap |
Proceeds From Payments For In Interest Bearing Deposits In Banks
ProceedsFromPaymentsForInInterestBearingDepositsInBanks
|
-1440 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1009116 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
80205864 | shares | |
cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
1178261 | shares | |
cprx |
Non Cash Incentive Received From Lessor
NonCashIncentiveReceivedFromLessor
|
131175 | ||
cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
1178261 | shares | |
dei |
Entity Registrant Name
EntityRegistrantName
|
CATALYST PHARMACEUTICALS, INC. | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7610997 | shares | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001369568 | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2016-09-30 | ||
us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
56497 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-10596916 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.17 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2016 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | ||
us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1290943 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6416715 | ||
us-gaap |
Depreciation
Depreciation
|
31442 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-779191 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
14966002 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-13909132 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13909132 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
2966113 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
277679 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-697403 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-738803 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1193883 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14966002 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-11265 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
94154 | ||
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
11265 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Organization and Description of Business.</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> Catalyst Pharmaceuticals, Inc. (the Company) is a development-stage biopharmaceutical company focused on developing and commercializing innovating therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), infantile spasms and Tourette’s Disorder.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s primary focus is on the development and commercialization of its drug candidates. The Company has incurred operating losses in each period from inception through September 30, 2016. The Company has been able to fund its cash needs to date through several public and private offerings of its common stock and warrants, through government grants, and through an investment by a strategic purchaser. See Note 9.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Capital Resources</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> On January 31, 2014, the Company filed a Shelf Registration Statement on Form S-3 (the 2014 Shelf Registration Statement) with the U.S. Securities Exchange Commission (SEC) to sell up to $100 million of common stock. This registration statement (file No. 333-193699) was declared effective by the SEC on March 19, 2014. The Company has conducted two registered direct offerings under the 2014 Shelf Registration Statement. See Note 9.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next year.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> The Company may raise required funds through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any such required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business.</p> </div> | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-13551764 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
88931 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div><b>b.</b> <table> <tr> <td align="left" valign="top"><b>USE OF ESTIMATES.</b> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table> </div> | ||
us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | ||
us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
4.64 | ||
us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
-11265 | ||
dei |
Trading Symbol
TradingSymbol
|
CPRX | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8549287 | ||
us-gaap |
Proceeds From Payments For In Interest Bearing Deposits In Banks
ProceedsFromPaymentsForInInterestBearingDepositsInBanks
|
3149198 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1347440 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
82867140 | shares | |
cprx |
Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
|
Three months | ||
cprx |
Number Of Offerings Under Shelf Registration
NumberOfOfferingsUnderShelfRegistration
|
2 | Offerings | |
cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | shares | |
CY2015Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
1059348 | |
CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
CY2015Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
CY2015Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1974757 | |
CY2015Q3 | us-gaap |
Depreciation
Depreciation
|
11259 | |
CY2015Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-521731 | |
CY2015Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
46659 | |
CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
5017428 | |
CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4449038 | |
CY2015Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4449038 | |
CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5017428 | |
CY2015Q3 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
591668 | |
CY2015Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3042671 | |
CY2015Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
330770 | |
CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
82470139 | shares |
CY2015Q3 | cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
374130 | shares |
CY2015Q3 | cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
374130 | shares |
CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
CY2016Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
CY2016Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1420015 | |
CY2016Q3 | us-gaap |
Depreciation
Depreciation
|
9482 | |
CY2016Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
106948 | |
CY2016Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
66981 | |
CY2016Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
3914014 | |
CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3953981 | |
CY2016Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3953981 | |
CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3914014 | |
CY2016Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2016Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2493999 | |
CY2016Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
532202 | |
CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
82870649 | shares |
CY2016Q3 | cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | shares |